PF 04937319
PF 04937319 structure
|
Common Name | PF 04937319 | ||
|---|---|---|---|---|
| CAS Number | 1245603-92-2 | Molecular Weight | 432.432 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C22H20N6O4 | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
|
Two dose-ranging studies with PF-04937319, a systemic partial activator of glucokinase, as add-on therapy to metformin in adults with type 2 diabetes.
Diabetes Obes. Metab. 17(8) , 751-9, (2015) To assess the efficacy and safety of a range of doses of a systemic, partial, glucokinase activator, PF-04937319, as add-on therapy to metformin, in patients with type 2 diabetes mellitus (T2DM).Patients were randomized to once-daily PF-04937319 doses of 10, ... |
|
|
Metabolites in safety testing assessment in early clinical development: a case study with a glucokinase activator.
Drug Metab. Dispos. 42(11) , 1926-39, (2014) The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide (PF-04937319), which is under development for the... |
|
|
The relationship of glucokinase activator-induced hypoglycemia with arteriopathy, neuronal necrosis, and peripheral neuropathy in nonclinical studies.
Toxicol. Pathol. 42(4) , 696-708, (2014) Glucokinase activators (GKAs) are being developed for the treatment of type 2 diabetes. The toxicity of 4 GKAs (PF-04279405, PF-04651887, piragliatin, and PF-04937319) was assessed in mice, rats, dogs, and/or monkeys. GKAs were administered for 2 to 8 weeks. ... |